Background: Phlebotomy represents the standard treatment option for iron overload in hemochromatosis (HC). Recently, red blood cell (RBC) apheresis has increasingly been used to remove iron. In this study we evaluated the depletion program of the newly developed Spectra Optia device.
Study Design And Methods: Adult male patients (n = 11) with HC were RBC depleted with the Spectra Optia device (Terumo BCT). In total, 24 procedures were performed. A volume of 300 to 550 mL of RBCs was withdrawn per single treatment.
Results: No significant adverse events were recorded. A median blood volume of 857.3 ± 23.3 mL was processed. The median procedure time was 12.0 ± 0.4 minutes. The mean reduction of Hct value in each procedure was approximately 6% (Hct pre 42.6 ± 0.5% vs. Hct post 36.6 ± 0.6%) and iron removed per procedure was 405.2 ± 23.3 mg.
Conclusion: The Spectra Optia device proved to be highly efficient in depleting RBCs in HC patients and allows for short procedure time. The Optia device can be safely used in this clinical setting. We recommend its use in case of severe iron overload if rapid iron depletion needs to be achieved and in case of cardiac compromise due to less blood volume removed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/trf.12949 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case Report of Therapeutic Plasma Exchange in Hypertriglyceridemia-Induced Pancreatitis.
Indian J Hematol Blood Transfus
October 2024
Department of Immunohematology & Blood Transfusion, Bharati Vidyapeeth Deemed University Medical College, Hospital & Research Centre, Pune, Maharashtra India.
To support the evidence of plasma exchange's ability to rapidly lower serum TG levels and provide upcoming research opportunities for evaluating the long-term effects of this treatment, we present the case of a 35-year-old female who was admitted for Hypertriglyceridemia-induced Pancreatitis (HTGP). She underwent Therapeutic Plasma Exchange (TPE) using Spectra Optia Apheresis System on an emergency basis. The patient had a remarkable reduction of serum Triglycerides (TG) from 3953 to 291 mg/dl, which was life saving.
View Article and Find Full Text PDFExtracorporeal Photopheresis with 5-Aminolevulinic Acid in Crohn's Disease-A First-in-Human Phase I/II Study.
J Clin Med
October 2024
Department of Gastroenterology, Akershus University Hospital, N-1478 Lorenskog, Norway.
With the increasing prevalence of Crohn's disease (CD), treatment options for patients who fail conventional and advanced therapy are highly needed. Therefore, we explored the safety and efficacy of extracorporeal photopheresis (ECP) using 5-aminolevulinic acid (ALA) and blue light (405 nm). Patients with active CD who failed or were intolerant to biological therapy were eligible.
View Article and Find Full Text PDFEvaluating a New Photopheresis System: A Comparison with Two Established Systems on Cell Yield and Collection Efficiency.
Diagnostics (Basel)
October 2024
Department for Transfusion Medicine, University Hospital of Salzburg, Paracelsus Medical University Salzburg, Muellner Hauptstraße 48, 5020 Salzburg, Austria.
Unlabelled: : Extracorporeal photopheresis (ECP) is a well-established and efficacious cell therapy for a range of diseases. The objective of this retrospective study was to compare the new Amicus Blue inline system with the Therakos Cellex inline system and the Spectra Optia offline system in terms of collection efficiency, mononuclear cell (MNC) yield of mononuclear cell products (MCPs), processing time and correlation between MCP cell count and peripheral blood count of patients.
Methods: This retrospective study compared 127 procedures utilizing the Spectra Optia offline system, 93 procedures employing the Amicus Blue inline system, and 81 procedures applying the Therakos Cellex inline system.
Quality of life in people with sickle cell disease treated with automated red blood cell exchange.
Vox Sang
October 2024
Terumo Blood and Cell Technologies, Zaventem, Belgium.
Article Synopsis
- This review focuses on how sickle cell disease (SCD) affects patients' quality of life (QoL) and evaluates the effectiveness of automated red blood cell exchange (aRBCX) in improving QoL for these patients.
- Some studies show that aRBCX can improve health-related QoL by reducing hospital stays and pain-related admissions, while others find no significant changes, and it may lead to increased complications and complex vascular access.
- Although aRBCX shows promise in enhancing QoL for SCD patients, more in-depth studies with patient feedback are needed, and an approach that includes psychological support and pain management might further improve their QoL.*
Performance and safety of therapeutic erythrocytapheresis in polycythemia and hemochromatosis treatment: single centre experience.
Hematol Transfus Cell Ther
November 2024
Clinical Department of Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, Zagreb, Croatia; University of Applied Health Sciences, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia; Department of Health Studies, University of Split, Split, Croatia.
Article Synopsis
- Therapeutic erythrocytapheresis is presented as a better alternative to therapeutic phlebotomy for treating polycythemia and hemochromatosis, with the study analyzing various cell separators used in the process.
- Over a 20-year period, 1731 erythrocytapheresis procedures were performed on 125 patients, primarily using the Haemonetics MCS+ separator, which showed significant reductions in hemoglobin and hematocrit levels.
- While the Haemonetics MCS+ effectively reduced blood components, the Spectra Optia device was quicker and removed a larger volume of red blood cells in less time, indicating both systems are efficient and beneficial for patients needing treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!